This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
by Zacks Equity Research
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case
by Zacks Equity Research
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
by Zacks Equity Research
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales
by Christopher Vargas
Walgreens (WBA) announced today that they would be suspending the sales of Sanofi's (SNY) heartburn medication Zantac.
Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy
by Zacks Equity Research
Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy
Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study
by Zacks Equity Research
Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
SNY or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Buy These 3 Stocks With Upgraded Broker Ratings Right Now
by Swayta Shah
After thorough research, brokers decide to rate a particular company's stock. Hence, one can be easily rely on the rating.
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
by Zacks Equity Research
Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Here's Why AstraZeneca (AZN) is Outperforming Its Industry
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Protalix Completes Enrollment in Third Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.
Moving Average Crossover Alert: Sanofi
by Zacks Equity Research
Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Are Investors Undervaluing Sanofi (SNY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet
by Zacks Equity Research
The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent
by Zacks Equity Research
Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.
Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Trovagene's Onvansertib Shows Response in Phase Ib AML Study
by Zacks Equity Research
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Alnylam Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.
Alnylam Begins Phase III Study on Onpattro for New Indication
by Zacks Equity Research
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
Abbott Partners With Sanofi to Upgrade Diabetes Management
by Zacks Equity Research
Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.
Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
by Zacks Equity Research
Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.